Compare WLFC & NEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WLFC | NEO |
|---|---|---|
| Founded | 1985 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Precision Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 1997 | 2008 |
| Metric | WLFC | NEO |
|---|---|---|
| Price | $191.35 | $8.25 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $160.00 | $11.14 |
| AVG Volume (30 Days) | 45.4K | ★ 1.3M |
| Earning Date | 05-05-2026 | 04-28-2026 |
| Dividend Yield | ★ 0.88% | N/A |
| EPS Growth | ★ 146.23 | N/A |
| EPS | ★ 13.89 | N/A |
| Revenue | ★ $569,223,000.00 | N/A |
| Revenue This Year | $2.75 | $10.63 |
| Revenue Next Year | $7.35 | $9.73 |
| P/E Ratio | $13.02 | ★ N/A |
| Revenue Growth | ★ 36.00 | N/A |
| 52 Week Low | $114.01 | $4.72 |
| 52 Week High | $207.05 | $13.74 |
| Indicator | WLFC | NEO |
|---|---|---|
| Relative Strength Index (RSI) | 64.10 | 46.31 |
| Support Level | $192.00 | $7.33 |
| Resistance Level | $206.77 | $8.89 |
| Average True Range (ATR) | 7.05 | 0.39 |
| MACD | 2.51 | 0.17 |
| Stochastic Oscillator | 97.18 | 74.92 |
Willis Lease Finance Corp, with its subsidiaries, is a lessor and servicer of commercial aircraft and aircraft engines. The company has two reportable business segments, which include Leasing and Related Operations and Spare Parts Sales. A majority of its revenue is generated from the Leasing and Related Operations segment, which involves acquiring and leasing, under operating leases, commercial aircraft, aircraft engines, and other aircraft equipment and the selective purchase and resale of commercial aircraft engines, aircraft equipment, and other related businesses. Geographically, the company derives maximum Lease rent revenue from the United States, followed by Europe, Asia-Pacific (excluding India), India, South America, Canada, Central America, and the Middle East.
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.